Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 19/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 16/20 | 1.00 |
| ▸ | CYP11B1 | P15538 | 10/20 | 1.00 |
| ▸ | MIF | P14174 | 1/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | TNF | P01375 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4230798 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1MIFPKM | |
| SCHEMBL4230787 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1MIFPKM | |
| Oxalic Acid SCHEMBL4231832 | 0.91 | CYP19A1 (0.82) | CYP19A1CYP11B2CYP11B1MIFPKM | |
| Oxalic Acid SCHEMBL4221262 | 0.91 | CYP19A1 (0.82) | CYP19A1CYP11B2CYP11B1MIFPKM | |
| SCHEMBL4231731 | 0.90 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1MIFPKM | |
| SCHEMBL4231728 | 0.90 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1MIFPKM | |
| SCHEMBL4231733 | 0.90 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1MIFPKM | |
| SCHEMBL13851846 | 0.87 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1MIFPKM | |
| SCHEMBL6825625 | 0.87 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1MIFPKM | |
| SCHEMBL6825622 | 0.87 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1MIFPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105278-A1 | Selective inhibitors of human corticosteroid syntheses | UNIVERSITAT DES SAARLANDES (DE) | 2009-04-23 | — | — | US | disclosed |
| EP-1768654-A2 | SELECTIVE INHIBITORS OF HUMAN CORTICOSTEROID SYNTHESES | Universität des Saarlandes (DE) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006008316-A2 | SELECTIVE INHIBITORS OF HUMAN CORTICOSTEROID SYNTHESES | Universität des Saarlandes (DE) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105278-A1 | Selective inhibitors of human corticosteroid syntheses | HSD11B1, HSD11B2, CYP11B1 | CYP19A1 76/4885CYP11B2 5/4885CYP11B1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.